<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454155</url>
  </required_header>
  <id_info>
    <org_study_id>BPSC030</org_study_id>
    <nct_id>NCT00454155</nct_id>
  </id_info>
  <brief_title>Study of Opebacan in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</brief_title>
  <acronym>HSCT</acronym>
  <official_title>A Phase I/II Study of the Safety and Pharmacokinetics of Opebacan (rBPI21) in Patients Undergoing Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>XOMA (US) LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>XOMA (US) LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are as follows:&#xD;
&#xD;
      To demonstrate the safety of escalating doses of opebacan in subjects undergoing&#xD;
      myeloablative allogeneic Hematopoietic Stem Cell Transplantation&#xD;
&#xD;
      To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic&#xD;
      Hematopoietic Stem Cell Transplantation&#xD;
&#xD;
      To determine if IV administration of opebacan is associated with changes in biological&#xD;
      markers for inflammation&#xD;
&#xD;
      To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem&#xD;
      Cell Transplantation related complications, including aGvHD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IV infusion of opebacan to replace endogenous BPI during the peritransplant period will&#xD;
      result in the reduction of LPS-induced inflammatory sequelae, in particular aGvHD, in&#xD;
      patients undergoing allogeneic HSCT.&#xD;
&#xD;
      The rationale for using opebacan in patients undergoing myeloablative regimens and HSCT is&#xD;
      based on the following:&#xD;
&#xD;
      Endotoxemia has been demonstrated to play a central pathophysiologic role as a trigger of&#xD;
      aGvHD in animal models.&#xD;
&#xD;
      Endotoxemia following HSCT is associated with inflammatory conditions (such as inflammatory&#xD;
      cytokine release) that have been demonstrated in humans to be associated with organ damage&#xD;
      and increased morbidity and mortality.&#xD;
&#xD;
      Endotoxemia and LBP elevation have been demonstrated in humans undergoing ablative HSCT.&#xD;
&#xD;
      Chemotherapy-induced neutropenia results in a deficiency of endogenous BPI levels.&#xD;
&#xD;
      The timing of the endotoxemic insult is predictable (i.e., subsequent to myeloablative&#xD;
      chemotherapy and radiotherapy).&#xD;
&#xD;
      The return to normal neutrophil levels is not immediate and takes one week to several weeks.&#xD;
&#xD;
      Well established laboratory techniques for surrogate markers related to LPS presence and its&#xD;
      activities can facilitate the evaluation of molecules designed to inhibit or antagonize LPS&#xD;
      and its effects.&#xD;
&#xD;
      The objectives of this study are as follows:&#xD;
&#xD;
      To demonstrate the safety of escalating doses of opebacan in subjects undergoing&#xD;
      myeloablative allogeneic Hematopoietic Stem Cell Transplantation&#xD;
&#xD;
      To determine the pharmacokinetics of opebacan in subjects undergoing myeloablative allogeneic&#xD;
      Hematopoietic Stem Cell Transplantation&#xD;
&#xD;
      To determine if IV administration of opebacan is associated with changes in biological&#xD;
      markers for inflammation&#xD;
&#xD;
      To develop preliminary descriptive data on the occurrence and severity of Hematopoietic Stem&#xD;
      Cell Transplantation related complications, including aGvHD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment&#xD;
  </why_stopped>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to engraftment</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory states</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant-related complications</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The pharmacokinetics of opebacan</measure>
    <time_frame>100 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Opebacan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opebacan</intervention_name>
    <description>4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days</description>
    <arm_group_label>Opebacan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &lt;= 60 and undergoing allogeneic HSCT&#xD;
&#xD;
          -  Life expectancy &gt; 8 weeks&#xD;
&#xD;
          -  Scheduled for treatment with a conditioning regimen intended to be myeloablative&#xD;
&#xD;
          -  Female subjects of child-bearing age must have a negative urine pregnancy test.&#xD;
             Sexually active male and female subjects of reproductive age must be using a form of&#xD;
             contraception considered effective and medically acceptable by the Investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cumulative lifetime exposure of &gt; 300 mg/M2 of anthracycline (expressed as doxorubicin&#xD;
             equivalent dose) or receipt of anthracycline within 180 days prior to initiating&#xD;
             conditioning for HSCT&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Prophylactic antibacterial antibiotics.&#xD;
&#xD;
          -  Positive for HIV, HTLV-I, or HTLV-II&#xD;
&#xD;
          -  Any prior stem cell transplant&#xD;
&#xD;
          -  Prior history of CHF&#xD;
&#xD;
          -  Cord blood is the source of a subject's transplanted cells.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eva C Guinan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>March 28, 2007</study_first_submitted>
  <study_first_submitted_qc>March 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <last_update_submitted>July 27, 2012</last_update_submitted>
  <last_update_submitted_qc>July 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HSCT</keyword>
  <keyword>AGVHD</keyword>
  <keyword>Myeloablative</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>Hematopoietic</keyword>
  <keyword>Stem</keyword>
  <keyword>Cell</keyword>
  <keyword>Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

